Russell Petry
Research Subjects
Russell Petry has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Chang Xu
Foundation Medicine, Inc., Boston, MA, USA
35 shared publications - Christopher J. Sweeney
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia
35 shared publications - David Fabrizio
Foundation Medicine Inc, Boston, Massachusetts, USA
35 shared publications - Jie He
Affiliation Foundation Medicine, Inc., Boston, Massachusetts, United States of America
35 shared publications - Kalpit Shah
Department of Translational Medicine—Oncology, Genentech, South San Francisco, CA
35 shared publications - Kobe Yuen
Genentech, South San Francisco, California
35 shared publications
Latest Publications
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of on-treatment ctDNA TF detection and 90% PSA reduction
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of on-treatment ctDNA TF detection and 90% PSA reduction
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Patient characteristics of the biomarker evaluable population (BEP) cohort
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Patient characteristics of the biomarker evaluable population (BEP) cohort
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Overall survival by biomarker evaluability
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Overall survival by biomarker evaluability
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
CtDNA tumor fraction pre-enzalutamide to prognosticate overall survival and progression-free survival on enzalutamide post-abiraterone
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
CtDNA tumor fraction pre-enzalutamide to prognosticate overall survival and progression-free survival on enzalutamide post-abiraterone
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
CtDNA tumor fraction and standard clinical features and associated hazard ratios
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
CtDNA tumor fraction and standard clinical features and associated hazard ratios
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of on-treatment ctDNA TF detection and 30% PSA reduction
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of on-treatment ctDNA TF detection and 30% PSA reduction
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
CtDNA tumor fraction to prognosticate overall survival on enzalutamide post-abiraterone by treatment arm
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
CtDNA tumor fraction to prognosticate overall survival on enzalutamide post-abiraterone by treatment arm
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of 90% PSA reduction
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of 90% PSA reduction
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of ctDNA by cut point
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of ctDNA by cut point
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of 50% PSA reduction
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Prognostic value of 50% PSA reduction